The Reporting Frequency of Ketoacidosis Events with Dapagliflozin from the European Spontaneous Reporting System: The DAPA-KETO Study

• Main Authors: Gabriella di Mauro (Author), Annamaria Mascolo (Author), Mario Gaio (Author), Concetta Rafaniello (Author), Antonella De Angelis (Author), Liberato Berrino (Author), Giuseppe Paolisso (Author), Francesco Rossi (Author), Annalisa Capuano (Author)
• Formato: Libro
• Publicado: MDPI AG, 2022-02-01T00:00:00Z.
• Subjects: article
• Acceso en liña: Connect to this object online.

Dapagliflozin was associated with an increased risk of diabetic ketoacidosis that has led to the European withdrawal of the authorization for the type 1 diabetes. However, it is still used for the treatment of type 2 diabetes. Therefore, we aim to evaluate the occurrence of dapagliflozin-induced ket...